Mazdutide
Also known as: IBI362, LY3305677
A glucagon/GLP-1 dual agonist developed for obesity and metabolic disorders.
Overview
Mazdutide is a dual glucagon and GLP-1 receptor agonist being developed primarily in China. It combines GLP-1 mediated appetite suppression with glucagon-mediated thermogenesis and lipolysis.
Mechanism of Action
Dual activation of GLP-1 and glucagon receptors provides complementary metabolic benefits. GLP-1 component reduces appetite while glucagon increases energy expenditure and hepatic lipid oxidation.
Pharmacokinetics
Weekly dosing formulation with sustained receptor engagement.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
3-9 mg
Once weekly
Ongoing
Dose-dependent efficacy
Research Areas
Key Research Findings
- 1Phase 3 trials in China showing significant weight loss (up to 16%)
- 2Improvements in glycemic control and liver fat
- 3Favorable cardiovascular risk marker changes
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Diarrhea
- Vomiting
Contraindications
- Pregnancy
- MTC/MEN2
Safety Considerations
GI side effects expected. Monitoring for hyperglycemia due to glucagon component.
Storage Requirements
Refrigerate at 2-8C
Scientific References
- 1